SUMMARY. We examined in conscious dogs the effects of /9-adrenergic receptor blockade on measurements of left circumflex coronary arterial diameter and blood flow and calculations of late diastolic coronary resistance and left circumflex coronary internal cross-sectional area. Propranolol (combined /3i-and 0 2 -adrenergjc receptor blockade) and atenolol (selective /S tadrenergic receptor blockade) elicited nearly identical effects. For example, propranolol and atenolol increased (P < 0.01) late diastolic coronary resistance by 13 ± 4.3 and 14 ± 3.0% and reduced (P < 0.01) large coronary cross-sectional area by 13 ± 1.5 and 12 ± 2.4%, respectively. This was associated with small reductions in heart rate (8 ± 2.0%) and left ventricular dP/dt (10 ± 1.8%). To determine whether the mechanism of coronary constriction involved the predominance of unopposed a-adrenergic receptor tone, the effects of propranolol and atenolol were examined in the presence of phentolamine (aj-and a 2 -adrenergic receptor blockade). Under these conditions plasma norepinephrine and epinephrine rose by 2114 ± 348 and 572 ± 139 pg/ml, respectively, and propranolol induced significantly greater (P < 0.01) increases in late diastolic coronary resistance (103 ± 23%) and decreases in large coronary cross-sectional area (25 ± 4.3%), heart rate (34 ± 3.8%) and left ventricular dP/dt (51 ± 4.3%), indicating that the mechanism probably did not involve a-adrenergic receptor activation. When heart rate was held constant, in the presence of phentolamine, propranolol elicited intermediate increases in late diastolic coronary resistance (39 ± 9.4%) and reductions in large coronary cross-sectional area (18 ± 3.6%) to those observed with propranolol in the presence and absence of phentolamine, but in spontaneous rhythm. In the presence of selective ai-adrenergic receptor blockade (prazosin), plasma catecholamines did not rise, and /S-adrenergic receptor blockade induced similar increases in late diastolic coronary resistance (15 ± 3.7%) and decreases in large coronary cross-sectional area (14 ± 4.0%) and left ventricular dP/dt (12 ± 2.4%), as observed in the absence of a-adrenergic receptor blockade. Thus, blockade of /3-adrenergic receptors elicits constriction of large coronary arteries in the conscious dog. This constriction is not diminished by a-adrenergic receptor blockade and is actually much greater after phentolamine, which blocks a]-and « 2 -adrenergic receptors, and elevates levels of catecholamines and, consequently, heart rate and myocardial contractility. The changes in coronary vasomotor tone were not accompanied by changes in A-VO 2 difference. These experiments do not support a direct action of /3-adrenergic stimulation and blockade on the coronary vessels. Thus, the constriction appears related to the blockade of /3]-adrenergic effects on heart rate and left ventricular dP/dt, i.e., those factors that alter myocardial metabolic demands and coronary blood flow, but does not appear to involve the predominance of unopposed aadrenergic receptor tone. (Circ Res 53: 389-400, 1983) /3-ADRENERGIC receptor blockers are utilized extensively in the therapy of coronary artery disease. Their mechanism of action primarily involves limitation of the imbalance between myocardial oxygen demand and supply, which can alleviate myocardial ischemia. When administered to anesthetized, openchest animals, these agents cause profound depression of heart rate, myocardial contractility, and coronary blood flow, but when given to conscious animals they induce relatively slight changes in either cardiac function or coronary dynamics (Pitt et al., 1970; Bergamaschi et al., 1971) . Most previous studies have characterized the effects of /3-adrenergic receptor blocking agents on the coronary circulation in terms of their action on measurements of coronary blood flow and arterial pressure and consequent calculation of coronary vascular resistance. With certain reservations concerning actual coronary driving pressure (Bellamy, 1978; Ellis and Klocke, 1980) , these techniques are relatively useful in characterizing the responses of coronary resistance vessels. However, it is also important to understand the effects of /3-adrenergic receptor blockade on large coronary arteries, since recent reports have suggested that these agents may exacerbate coronary artery spasm (Robertson et al., 1982) . These data are less available, mainly because of limitation of methodology to measure large coronary artery dimensions in vivo. Recently, we developed techniques to assess large coronary arterial dimensions instantaby guest on
/3-ADRENERGIC receptor blockers are utilized extensively in the therapy of coronary artery disease. Their mechanism of action primarily involves limitation of the imbalance between myocardial oxygen demand and supply, which can alleviate myocardial ischemia. When administered to anesthetized, openchest animals, these agents cause profound depression of heart rate, myocardial contractility, and coronary blood flow, but when given to conscious animals they induce relatively slight changes in either cardiac function or coronary dynamics (Pitt et al., 1970; Bergamaschi et al., 1971) . Most previous studies have characterized the effects of /3-adrenergic receptor blocking agents on the coronary circulation in terms of their action on measurements of coronary blood flow and arterial pressure and consequent calculation of coronary vascular resistance. With certain reservations concerning actual coronary driving pressure (Bellamy, 1978; Ellis and Klocke, 1980) , these techniques are relatively useful in characterizing the responses of coronary resistance vessels. However, it is also important to understand the effects of /3-adrenergic receptor blockade on large coronary arteries, since recent reports have suggested that these agents may exacerbate coronary artery spasm (Robertson et al., 1982) . These data are less available, mainly because of limitation of methodology to measure large coronary artery dimensions in vivo. Recently, we developed techniques to assess large coronary arterial dimensions instanta-neously and continuously in the conscious dog , so that these questions could be evaluated systematically.
The first question to be answered by this investigation was whether £-adrenergic receptor blockers induce constriction of large coronary arteries in the conscious animal. The second goal of the study was to determine the mechanism of the constriction. This involved determining whether the constriction occurred by blocking only /3i-or combined #1-and /3 2 -adrenergic receptors, and then determining whether the constriction was mediated by inhibition of $-adrenergic tone and changes in myocardial metabolic demands or due to release of unopposed aadrenergic tone. This latter mechanism has gained wide acceptance (Parratt, 1980) , but has never been documented convincingly in the intact animal. We intended to examine the extent of utilization of this potential mechanism, by comparing the effects of /3-adrenergic receptor blockade in the presence and absence of a-adrenergic receptor blockade. If the mechanism involved release of unopposed a-adrenergic tone, then constriction should have been less in the animals pretreated with a-adrenergic receptor blockade.
Methods
Transducers were implanted through a left thorocotomy approach in adult, mongrel dogs of either sex and weighing an average of 36 ± 1.2 (SEM) kg, anesthetized with pentobarbital Na, 30 mg/kg, and using sterile surgical techniques. Miniature solid state pressure gauges were implanted in the left ventricle and aorta. Tygon catheters were implanted in the left atrium and descending thoracic aorta, and in five dogs in the coronary sinus. Stimulation electrodes were sutured to the outflow tract of the right ventricle and right atrium. A pair of ultrasonic dimension transducers, 7 MHz piezoelectric crystals ( 1 X 2 mm and approximately 12 mg in weight) were attached to dacron backing, and were sutured to opposing surfaces of the left circumflex coronary artery 2-4 cm from its origin. Electromagnetic or Doppler ultrasonic flow transducers were implanted on the same artery. When the electromagnetic technique was used, a hydraulic occluder was implanted distal to the flow transducer.
Left ventricular (LV) and aortic pressures were measured with the implanted solid state transducers. The transducers were calibrated in vitro before implantation, and were cross-calibrated daily, in vivo, with measurements of arterial and left atrial pressures, using the implanted catheters and Statham P23Db strain gauge manometers (Statham Instruments). Instantaneous and continuous measurements of external left circumflex coronary arterial diameter were obtained by means of an improved ultrasonic transit-time dimension gauge . Repeated calibration reference signals eliminated the electronic drift in the instrumentation and recording apparatus. The details of these techniques have been described previously (Patrick et al., 1974; Pagani et al., 1978; Vatner et al., 1980) . Coronary blood flow was measured instantaneously either with a Benton square wave electromagnetic flowmeter (Benton Instruments), or with a Doppler ultrasonic flowmeter (Franklin et al., 1966; Vatner et al., Circulation Research/Vo/. 53, No. 3, September 1983 1970). When the electromagnetic flow transducers were used, zero flow reference was established by brief coronary artery occlusion with the implanted hydraulic occluder. To determine whether the instrumentation implanted on the coronary artery affected measurements of coronary blood flow in the distribution of the instrumented artery, we also carried out measurements of regional myocardial blood flow in four dogs, using the radioactive microsphere Sc were suspended in 0.01% Tween 80 solution and agitated for 1 hour prior to experiments. One to two million microspheres, suspended in 10% dextran, were injected through the catheter implanted in the left atrium for determination of blood flow. A reference sample of arterial blood was withdrawn (7.75 ml/min) from the aortic catheter. At the end of the experiments, these four dogs were killed. Myocardial samples from the anterior left ventricle (distribution of noninstrumented coronary artery) and posterior left ventricle (distribution of instrumented coronary artery) were counted in a 7-well counter (Searle Analytic). The blood flow values were computed after correcting the raw counts for background and crossover. In four dogs, plasma catecholamines were measured by the method of DaPrada and Zurcher (1976) before and after phentolamine and before and after prazosin. In five dogs, arterial and coronary sinus O 2 contents were measured with a Lex O2 Con Oximeter (Lexington Instruments).
The experiments were conducted in healthy conscious dogs 10 days to 6 weeks postoperatively. All drugs were injected iv. Only one protocol was utilized on one experimental day. At least 2 days elapsed between experiments in the same animals. In the same six dogs, propranolol (0.5 mg/kg administered in two doses 5 minutes apart), which blocks $1-and j3 2 -adrenergic receptors, and atenolol (0.5 mg/kg administered in two doses 5 minutes apart), which selectively blocks /Si-adrenergic receptors, were administered on separate days. In four other dogs, radioactive microspheres were injected before and after propranolol. In 11 other dogs, blockade of a t -and a 2 -adrenergic receptors was achieved with phentolamine (2 mg/kg) followed by a continuous infusion (1 mg/min). Then propranolol (1 mg/kg, or 0.5 mg/kg in two doses 5 minutes apart) was administered in the presence of phentolamine. These experiments were carried out in spontaneous rhythm and with heart rate held constant. In four other dogs (the same four dogs which received microspheres after simple /3-adrenergic receptor blockade), radioactive microspheres were injected before and after propranolol, but in the presence of phentolamine. On a separate day in seven of the 11 dogs that received propranolol after phentolamine, atenolol (1 mg/kg, or 0.5 mg/kg in two doses 5 minutes apart) was administered in the presence of phentolamine. In three other dogs, butoxamine (3.0 mg/kg) was administered after atenolol in the presence of phentolamine. The effects of 0.5 mg/kg of either propranolol or atenolol were indistinguishable from those of the 1.0 mg/kg dose. In six dogs, prazosin was administered iv, (1 mg/kg) to block ai-adrenergic receptors, followed by atenolol (1.0 mg/kg). In four dogs, propranolol (1.0 mg/kg) was administered after prazosin (1 mg/kg). In eight dogs, phentolamine and prazosin were administered on separate days after j3-adrenergic blockade and with heart rate kept constant by ventricular pacing.
The effectiveness of blockade was tested for all drugs. Propranolol effectively blocked the inotropic and the depressor responses to isoproterenol (0.5 ^g/kg), whereas atenolol only blocked the inotropic response to this dose of isoproterenol. This dose of atenolol does not inhibit either the decrease in arterial pressure or maximal decrease in iliac vascular resistance in response to isoproterenol Vatner et al., 1982) . Phentolamine effectively blocked the pressor response to norepinephrine (0.5 fig/kg) , prazosin blocked the pressor response to norepineprhine (0.5 /zg/kg), and prazosin blocked the pressor response to a phenylephrine challenge (5.0 ng/ kg). Butoxamine (3 mg/kg) only partially blocked the increase in cardiac output and decreases in mean arterial pressure and total peripheral resistance induced by isoproterenol (0.2 jig/kg), in two dogs with cardiac denervation produced by the technique of Randall et al. (1980) . However, this dose of butoxamine also attenuated the rise in heart rate and LV dP/dt induced by isoproterenol (0.2 jig/kg). The results of these two experiments are presented in detail in Table 1 .
Data were recorded continuously on magnetic tape (Bell and Howell Corp., Data Tape Division) and played back on a multichannel oscillograph (Gould-Brush). Mean arterial pressure, coronary arterial diameter, and coronary blood flow are derived using RC filters with 2-second time constants. LV dP/dt was derived from the LV pressure signal using operational amplifiers (Teledyne-Philbrick) connected as differentiators and having frequency responses of 700 Hz. A triangle wave was substituted for the pressure signal to calibrate the differentiator directly. Heart rate was measured with a cardiotachometer triggered by the left ventricular pressure pulse. While external coronary artery diameter was measured continuously, the internal radius was calculated by determining at autopsy the thickness and mass of the vessel. Thus, wall volume was calculated as the quotient of mass and density. Knowing the wall volume, thickness, and external diameter, we calculated the internal diameter and CSA. Late diastolic coronary resistance (LDCR), an index of small coronary vessel resistance, was calculated as the quotient of late diastolic aortic pressure and late diastolic coronary blood flow. Mean ± SEM were calculated for all variables. Data were analyzed statistically using analysis of variance (Armitage, 1974) .
Results
Changes from baseline, either in actual values or percent change, are presented in these results. The baseline values are noted in figures and tables.
Effects of /3-Adrenergic Receptor Blockade
(n = 6) Atenolol reduced heart rate by 5.8 ± 0.9 beats/ min and increased mean arterial pressure by 4.4 ± 0.9 mm Hg. LV systolic pressure did not change, while LV end-diastolic pressure rose by 1.1 ± 0.2 mm Hg, and LV dP/dt fell by 365 ± 62 mm Hg/ sec. This was accompanied by a reduction in CSA (12 ± 2.4%) and increase in LDCR (14 ± 3.0%), while mean coronary blood flow did not change. All these changes were significant (P < 0.01).
Propranolol reduced heart rate by 6.5 ± 2.0 beats/ min and increased mean arterial pressure by 3.0 ± 0.9 mm Hg. LV systolic pressure did not change, while LV end-diastolic pressure rose by 1.6 ± 0.4 mm Hg, and LV dP/dt fell by 347 ± 67 mm Hg/ sec. This was accompanied by a reduction in CSA (13 ± 1.5%) and increase in LDCR (13 ± 4.3%), while mean coronary blood flow did not change significantly. All these changes were significant (P < 0.01). None of these changes were significantly different from those induced by atenolol.
To test the possibility that the implanted transducers interrupted normal innervation to the posterior wall and that perhaps different responses would be found in the anterior wall, we conducted four experiments with radioactive microspheres and measured coronary blood flow and calculated coronary resistance in both the anterior and posterior walls. In the four experiments in which radioactive microspheres were used, propranolol reduced mean transmural coronary blood flow nonsignificantly in the anterior (-14 ± 10%) and posterior (-13 ± 10%) walls of the left ventricle, and increased mean coronary resistance by 33 ± 15 and 29 ± 15%, respectively, in the anterior and posterior walls of the left ventricle.
Effects of a-Adrenergic Receptor Blockade
Phentolamine (n = 12) reduced mean arterial pressure by 16 ± 2.4 mm Hg and increased heart rate by 85 ± 8.6 beats/min. LV systolic and enddiastolic pressures fell by 12 ± 2.2 jnd 5.5 ± 0.5 mm Hg, respectively, and LV dP/dt rose by 1380 ± 245 mm Hg/sec. This was accompanied by an increase in mean left circumflex coronary blood flow (79 ± 19%) and CSA (35 ± 8.5%) and reduction in LDCR (46 ± 4.5%). All these changes were significant (p < 0.05) ( Table 1) . Phentolamine also increased plasma norepinephrine from 241 ± 54 to 2355 ± 372 pg/ml and plasma epinephrine from 66 ± 6 to 638 ± 138 pg/ml. Prazosin (n = 6) reduced mean arterial pressure by 18 ± 3.7 mm Hg, LV systolic pressure by 19 ± 3.4 mm Hg, and LV end-diastolic pressure by 3.9 ± 0.4 mm Hg, and increased heart rate by 25 ± 3.8 beats/min, whereas LV dP/dt did not change significantly. This was accompanied by an increase in CSA of 34 ± 9.2% and mean coronary blood flow of 28 ± 8.2%, and a reduction in LDCR (37 ± 3.7%). These changes were all signficant, P < 0.02. Prazosin did not increase either plasma norepinephrine or epinephrine. (Fig. 1) Atenolol in the presence of phentolamine (n = 7) reduced heart rate by 55 ± 9.7 beats/min, and LV dP/dt by 2680 ± 373 mm Hg/sec, while it increased LV end-diastolic pressure by 5.6 ± 0.8 mm Hg and mean arterial pressure by 11 ± 2.6 mm Hg and did not change LV systolic pressure. This was accompanied by reductions in mean left circumflex coronary blood flow (36 ± 5.0%) and CSA (29 ± 4.9%) and increases in LDCR (122 ± 24%). All these changes were significant [P < 0.05 (Table 2) ], and were significantly greater (P < 0.01) than were observed in the absence of phentolamine (Figs. 2  and 3 ).
Effects of 0-Adrenergic Receptor Blockade in the Presence of a-Adrenergic Receptor Blockade
In three dogs in which atenolol was given after phentolamine, butoxamine (3.0 mg/kg) was administered. The results of these three experiments are shown in Figure 4 . This dose of butoxamine reduced left circumflex CSA slightly, but not significantly, and reduced LV dP/dt, but not heart rate, significantly.
Propranolol in the presence of phentolamine (n = 11) reduced heart rate by 58 ± 8.2 beats/min, and LV dP/dt by 2487 ± 276 mm Hg/sec, while it increased LV end-diastolic pressure by 4.8 ± 0.9 mm Hg and mean arterial pressure by 11 ± 2.7 mm Hg and did not change LV systolic pressure. This was accompanied by reductions in mean left circumflex coronary blood flow (36 ± 4.9%) and CSA (25 ± * Post-phentolamine baseline significantly different from pre-phentolamine baseline, P < 0.01 f Significant change from phentolamine baseline with /3-block , P < 0.01 % Significant change from phentolamine baseline with |9-block, P < 0 05. 4.3%) and increases in LDCR (103 ± 23%). All these changes were significant (Table 2) (P < 0.05) and were significantly greater, (P < 0.01) than were observed in the absence of phentolamine (Figs. 5 and 6). Moreover, none of these changes were significantly different from those observed with atenolol (Table 2 ).
AP
In the four experiments with radioactive microspheres, propranolol reduced mean transmural coronary blood flow by 43 ± 11% and 37 ± 11%, respectively, in the anterior and posterior walls of the left ventricle, while increasing calculated mean coronary resistance by 155 ± 22% and 147 ± 23%, respectively, in the anterior and posterior walls of the left ventricle. In five dogs, arterial and coronary sinus O 2 con- tents were measured prior to phentolamine, after phentolamine, and after atenolol plus phentolamine. No significant changes in A-VO2 differences were observed, i.e., A-VO2 difference was not reduced in the presence of the coronary vasodilation induced by phentolamine, and A-VO2 difference was not widened in the presence of the coronary vasoconstriction induced by atenolol (Table 3) . With heart rate constant at 165 ± 6.0 beats/min, propranolol reduced LV dP/dt by 1745 ± 250 mm Hg/sec, while it increased LV end-diastolic pressure by 3.0 ± 0.3 mm Hg, and mean arterial pressure by 12 ± 3.5 mm Hg, and did not change LV systolic pressure (Table 4 ). This was accompanied by reductions in CSA (18 ± 3.6%) and increases in LDCR (39 ± 9.4%), while coronary blood flow fell insignificantly. These changes were significant [P < 0.01 (Table 4) ] and were significantly less (P < 0.01) than those when heart rate varied spontaneously (Figs. 5 and 6).
FIGURE 4. In these three experiments, butoxamine was administered after phentolamine and atenolol Significant reductions occurred in left circumflex coronary cross-sectional area (CSA), LV dP/dt, heart rate (HR), and mean coronary blood flow (CBF) and increases in arterial pressure (AP) and mean coronary resistance (MCR) with atenolol. Butoxamine tended to reduce coronary dimensions further. The only significant effect was the further reduction in LV dP
Atenolol in the presence of prazosin (n = 4) reduced heart rate by 21 ± 3.2 beats/min, and LV dP/dt by 502 ±139 mm Hg/sec, while it increased LV end-diastolic pressure by 2.4 ± 0.5 mm Hg and mean arterial pressure by 3.8 ±1.0 mm Hg and did not change LV systolic pressure significantly. This was accompanied by reductions in mean left circumflex coronary blood flow (6.3 ± 1.5%) and CSA (14 ± 4.0%) and increases in LDCR (15 ± 3.7%). All these changes with atenolol were significant (P < 
DPropranolol
• Phentolamine + Propranolol Phentolamine + Propranolol HR constant 0.02) and were significantly less (P < 0.01) than were observed in the presence of phentolamine (Figs. 2 and 3) . Propranolol in the presence of prazosin {n = 4) reduced heart rate by 22 ± 6.2 beats/min, and LV dP/dt by 614 ± 125 mm Hg/sec, while it increased LV end-diastolic pressure by 2.0 ± 0.2 mm Hg and mean arterial pressure by 2.8 ±1.4 mm Hg and did not change LV systolic pressure significantly. This was accompanied by reductions in mean left circumflex coronary blood flow (13.7 ± 3.2%) and CSA (16 ± 2.9%) and increases in LDCR (16 ± 3.6%). All these changes with propranolol were similar to those observed with atenolol after prazosin.
FIGURE 6. Effects of propranolol alone (open bars), propranolol in the presence of phentolamine (solid bars), and propranolol in the presence of phentolamine with heart rate constant (shaded bars) are compared as percent changes from baseline for mean coronary blood flow (CBF), late diaslolic coronary resistance (LDCR), and left circumflex coronary cross-sectional area (CSA). Baseline values are shown beneath the bars. Propranolol induced significantly greater constriction of large coronary arteries and resistance vessels in the presence

Effects of a-Adienergic Blockade in the Presence of /?-Adrenergic Receptor Blockade with
Propranolol and with Heart Rate Constant (n = 8) (Fig. 7) With heart rate constant and prior 0-adrenergjc receptor blockade, phentolamine reduced mean arterial pressure by 19 ± 2.4 mm Hg, LV systolic pressure by 20 ± 4.4 mm Hg, LV end-diastolic pressure by 2.2 ± 0.5 mm Hg, and LV dP/dt by 500 ± 84 mm Hg/sec. This was accompanied by reductions in LDCR (11 ± 2.8%) and nonsignificant changes in coronary blood flow and CSA.
With heart rate constant, prazosin reduced mean arterial pressure by 21 ± 2.0 mm Hg, LV systolic pressure by 15 ± 2.5 mm Hg, LV end-diastolic pressure by 2.6 ± 0.5 mm Hg, and LV dP/dt by 287 ± 62 mm Hg/sec. This was accompanied by nonsignificant changes in left circumflex coronary blood flow and CSA, but a reduction in LDCR (22 ± 2%).
Discussion
We recently observed that /S-adrenergic receptor stimulation dilates large coronary arteries in the conscious dog (Vatner et al., 1982) . Although stimulation of /3-adrenergjc receptors causes dilation, this does not necessarily imply that the reverse is correct, i.e., that blockade of /3-adrenergic receptors causes vasoconstriction. In fact, whereas studies in anesthetized animals have indicated that /3-adrenergjc receptor blockade induces profound effects on cardiac dynamics and, consequently, substantial reductions in coronary blood flow and increases in calculated coronary vascular resistance (Parratt, 1980) , studies conducted in conscious animals have indicated relatively slight effects on the coronary circulation (Pitt et al., 1970; Bergamaschi et al., 1971 ). Our results on coronary blood flow and calculated coronary vascular resistance are consistent with those of Pitt et al. (1970) and Bergamaschi et al. (1971) , i.e., either selective jSi-adrenergic receptor blockade with atenolol or combined /3j-and $2-adrenergjc receptor blockade with propranolol induced nonsignificant effects on coronary blood flow and small, but statistically significant, increases in LDCR.
In view of the potential role of /3-adrenergjc mechanisms in mediating vasospasm of large coronary arteries and the recent reports suggesting that vasospastic angina is exacerbated by propranolol (Robertson et al., 1982) , it was considered important to determine the effects of (3-adrenergic receptor blockade on large coronary arteries. The results of the present investigation indicate that propranolol, which blocks #1-and j9 2 -adrenergic receptors, induces modest constriction of large coronary arteries in the conscious dog. Several possible mechanisms for the propranolol-induced constriction of the large coronary arteries were considered; (1) blockade of 02 vasodilator tone, (2) a direct effect of propranolol on the coronary arteries, (3) predominance of unopposed a-adrenergic tone, and (4) blockade of /Sieffects and concomitant reduction in myocardial metabolic demands.
If the mechanism involved blockade of /3 2 -adrenergic receptor vasodilator tone, then atenolol, which selectively blocks /3]-adrenergic receptors, should not evoke the constriction. Since atenolol and propranolol were found to elicit similar amounts of vasoconstriction, it is unlikely that the major mechanism of constriction involves elimination of ft-adrenergic vasodilator tone. In fact, the results of this study, demonstrating almost identical effects with propranolol and atenolol, suggest that the major mechanism of the coronary vasoconstriction involves blockade of ft-adrenergic tone. It is important to note that the dose of atenolol used, 0.5-1.0 mg/ kg, is sufficient to block ft-adrenergic receptors, but does not block the depressor and vasodilator effects of isoproterenol. The important consideration for the present study, however, is that propranolol and a dose of atenolol, which blocks only ft-adrenergic receptors, induced almost identical effects (Table 2) .
Although these experiments demonstrate important regulation by ft-adrenergic mechanisms, they do not eliminate a role for ft-adrenergic receptors. Our experiments with butoxamine were inconclusive. Butoxamine (3 mg/kg) is thought to induce selective /S 2 -adrenergic receptor blockade (Levy, 1966) . We found that this dose in conscious dogs, either intact, or with total cardiac denervation (Table  1) , only partially reduced the fall in arterial pressure, total peripheral resistance, and rise in cardiac output induced by an isoproterenol challenge, indicating that the ft-adrenergic receptor blocking action was incomplete. Moreover, this dose of butoxamine also reduced the inotropic and chronotropic responses to the isoproterenol challenge, suggesting that it might possess ft-adrenergic receptor blocking action as well. The effects on heart rate and LV dP/dt could not be attributed to reflex changes, since in these dogs the hearts were denervated. When butoxamine was administered after atenolol in the presence of phentolamine (Fig. 4) , it induced little further reduction in left circumflex coronary CSA or increase in late diastolic resistance. These experiments do not support an important role for ft-adrenergic receptors in mediating the vasoconstriction elicited by ft adrenergic receptor blockade in the presence of aadrenergic receptor blockade.
One prevalent theory explaining the constriction of coronary arteries following administration of ft adrenergic receptor blockers is that a-adrenergic tone becomes unopposed and consequently a-vasoconstriction predominates (Parratt, 1980) . To test this hypothesis, the ftadrenergic receptor blockers were administered after blockade of a-adrenergic receptors. Under these conditions, if release of unopposed a-adrenergic tone was important, then the vasoconstrictor effects of the ftadrenergic receptor blocking agents would be eliminated, or at least diminished. This was not observed. In fact, the constriction of resistance coronary arteries as reflected by measurements of LDCR, as well as the constriction of large coronary arteries as reflected by reductions in CSA, was augmented significantly (Figs. 1, 3, 5) . The enhanced constriction was probably due to the markedly elevated levels of norepinephrine and epinephrine observed after phentolamine. It is well recognized, and found in this study Circulation Research/Vo/. 53, No. 3, September 1983 as well, that phentolamine blocks a 2 -in addition to ai-adrenergic receptors thereby causing enhanced levels of circulating catecholamines (Graham et al., 1980) . It is possible that implantation of the transducers impaired neural innervation and prevented the expression of unopposed a-adrenergic tone. To study this possibility, experiments with radioactive microspheres were utilized. If the normal innervation, which follows the epicardial coronary arteries (Feigl, 1983) , was interrupted, dissimilar effects should have been observed in anterior and posterior sections of the left ventricle. The experiments in which myocardial blood flow was measured in both these regions after implantation of the transducers on the left circumflex coronary artery, demonstrated similar results in anterior and posterior sections of the left ventricle. Thus, unopposed a-adrenergic tone did not play a major role at the arteriolar level in our experiments. An effect on the large coronary arteries, although unlikely, cannot be completely discounted, since it was impossible to measure coronary arterial dimensions with our methodology in a remote, non-instrumented segment of coronary artery.
The greater constriction observed with /3-adrenergic receptor blockade in the presence of phentolamine was most likely related to the change in baseline levels, i.e., increases in CSA and reductions in LDCR. These changes were, in turn, most likely secondary to the increases in heart rate and myocardial contractility induced by phentolamine. The increased heart rate and LV dP/dt after phentolamine was ftadrenergically mediated, since phentolamine actually reduced LV dP/dt in the presence of ft adrenergic receptor blockade (Fig. 6) . The increases in heart rate and LV dP/dt induced by phentolamine in the absence of ftadrenergic receptor blockade most likely involved its action to block a 2 -as well as a\-receptors. This conclusion is supported by the differing effects observed with prazosin, where only ai-adrenergic receptors were blocked. Furthermore, in the presence of prior ftadrenergic receptor blockade, administration of either phentolamine (which blocks a\-and a 2 -adrenergic receptors) or prazosin (which blocks «i receptors selectively) failed to increase large coronary arterial cross-sectional area, although it is important to note that arterial pressure was reduced. Regardless, the results of this investigation indicate that the mechanism of release of unopposed a-adrenergic tone is not an important one in mediating the coronary artery vasoconstriction induced by ftadrenergic receptor blockers in otherwise normal, healthy, conscious dogs. This does not indicate that a-adrenergic vasoconstrictor mechanisms are not more readily identifiable after ftadrenergic blockade. It still holds that, under conditions where ftadrenergic receptor stimulation induces dilation, e.g., sympathetic nerve stimulation (Feigl, 1967) , elimination of this opposing influence does allow clearer expression of the opposing a-adrenergic effects on the coronary circulation (Feigl, 1967) .
Recently, we noted that large coronary arteries are responsive to changes in myocardial metabolic demands i.e., either increases in heart rate or ventricular wall tension induces dilation of large coronary arteries (Macho et al., 1980) . The results of the current investigation are compatible with these concepts. In the intact, resting conscious dog, /3-adrenergic receptor blockade induced only modest depression of heart rate and myocardial contractility, and concomitantly elicited only modest constriction of large coronary arteries. In the presence of phentolamine, j3-adrenergic blockade elicited striking reductions in heart rate and myocardial contractility and, consequently, elicited more intense constriction of large coronary arteries as well as coronary resistance vessels. Under these conditions, when heart rate was held constant, and only myocardial contractility fell with the |9-adrenergic receptor blocking agent, the constrictor effects on the resistance and large coronary arteries were less marked (Table 4) . These observations are consistent with the concept that large coronary arteries are responsive to changes in myocardial metabolic demands. The mechanism by which a change in myocardial metabolic demand might influence large coronary arterial dimensions is not known. Whereas it is known that adenosine concentration in the pericardial fluid varies with metabolic activity in the heart, this method of transmission of a metabolic message is unlikely, since the pericardium was incised widely at operation and not repaired. Another consideration is that the large coronary arteries are regulated by changes in coronary blood flow, as has been proposed by Gerova et al. (1980) . We have recently observed that the reactive dilation of large coronary arteries secondary to brief periods of coronary occlusion and myocardial ischemia can be totally prevented by preventing the reactive hyperemia upon release of the coronary occlusion, whereas the increase in large coronary arterial dimensions secondary to increasing heart rate or adenosine administration is only partially attenuated (Hintze and Vatner, in press ).
An alternative explanation for the almost identical amounts of the constriction of coronary arteries induced by atenolol and propranolol is that /3j-adrenergic receptors in coronary arteries were blocked and baseline /?i -adrenergic receptor tone was eliminated. Although studies in isolated coronary arterial preparations suggest that the vascular /J-adrenergic receptors are of the #1 -subtype (Baron et al., 1972; De La Lande et al., 1974; Drew and Levy, 1972; Johannson, 1973) , there is little evidence in more intact preparations to support this concept. Furthermore, if the coronary vasodilation induced by the catecholamines release consequent to phentolamine's action to block a 2 -adrenergic receptors was due to a direct vasodilator effect on coronary vessels independent of myocardial metabolic demand, coronary sinus O 2 content should have risen and A-VO 2 difference should have narrowed. This was not observed (Table 3) . Moreover, the coronary vasoconstriction induced by atenolol in the presence of phentolamine was not accompanied by a widening of A-VO2 difference. These results do not exclude a direct action of £1-or j8 2 -adrenergic stimulation and blockade on coronary arteries, but render this potential mechanism less likely.
In conclusion, the results of the present investigation indicate that jS-adrenergic receptor blockers, which are widely used in the clinical setting, can induce significant constriction of large coronary arteries. In the presence of elevated £1 -adrenergic tone and/or metabolic vasodilation, the administration of either a cardioselective or nonselective jS-adrenergic blocker invokes substantial constriction of large coronary arteries.
